Device manufacturers at risk for an FDA inspection in the coming months shouldn't expect to see any major changes in the agency's audit approach. That's because its new "program alignment" inspectional scheme isn't ready for primetime – mostly because a training program for investigators still needs to be stood up, an FDA official says.
Under program alignment, facility inspections performed by the Office of Regulatory Affairs will be restructured along commodity-specific product lines, including a team focused on device inspections
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?